Serum 25-hydroxyvitamin D levels are associated with prognosis in hematological malignancies

References

• Holick MF. The influence of vitamin D on bone health across the life cycle. J Nutr 2005;135:2726S–7S.
   PubMed Web of Science ®Google Scholar
• Holick MF. Vitamin D deficiency. N Engl J Med 2007;357:266–81.
   PubMed Web of Science ®Google Scholar
• Elias J, Marian B, Edling C, Lachmann B, Noe CR, Rolf SH, et al.. Induction of apoptosis by vitamin D metabolites and analogs in a glioma cell line. Recent Results Cancer Res 2003;164:319–32.
   PubMedGoogle Scholar
• Freedman DM, Looker AC, Chang SC, Graubard BI. Prospective study of serum vitamin D and cancer mortality in the United States. J Natl Cancer Inst 2007;99:1594–602.
   PubMed Web of Science ®Google Scholar
• Garland CF, Garland FC, Gorham ED, Lipkin M, Newmark H, Mohr SB, et al.. The role of vitamin D in cancer prevention. Am J Public Health 2006;96:252–61.
   PubMed Web of Science ®Google Scholar
• Robsahm TE, Tretli S, Dahlback A, Moan J. Vitamin D from sunlight may improve the prognosis of breast-, colon- and prostate cancer (Norway). Cancer Causes Control 2004;2:149–58.
   Google Scholar
• Zhou W, Heist RS, Liu G, Asomaning K, Neuberg DS, Hollis BW, et al.. Circulating 25-hydroxyvitamin D levels predict survival in early-stage non-small lung cancer patients. J Clin Oncol 2007;25:479–85.
   PubMed Web of Science ®Google Scholar
• Giovannucci E, Liu Y, Rimm EB, Hollis BW, Fuchs CS, Stampfer MJ, et al.. Prospective study of predictors of vitamin D status and cancer incidence and mortality in men. J Natl Cancer Inst 2006;98:451–9.
   PubMed Web of Science ®Google Scholar
• Gorham ED, Garland CF, Garland FC, Grant WB, Mohr SB, Lipkin M, et al.. Vitamin D and prevention of colorectal cancer. J Steroid Biochem Mol Biol 2005;97:179–94.
   PubMed Web of Science ®Google Scholar
• Ahonen MH, Tenkanen L, Teppo L, Hakama M, Tuohimaa P. Prostate cancer risk and prediagnostic serum 25-hydroxyvitamin D levels (Finland). Cancer Causes Control 2000;11:847–52.
   PubMed Web of Science ®Google Scholar
• Feskanich D, Ma J, Fuchs CS, Kirkner GJ, Hankinson SE, Hollis BW, et al.. Plasma vitamin D metabolites and risk of colorectal cancer in women. Cancer Epidemiol Biomarkers Prev 2004;13:1502–8.
   PubMed Web of Science ®Google Scholar
• Goodwin PJ, Ennis M, Pritchard KI, Koo J, Hood N. Prognostic effects of 25-hydroxyvitamin D levels in early breast cancer. J Clin Oncol 2009;27:3757–63.
   PubMed Web of Science ®Google Scholar
• Dietary supplement fact sheet: vitamin D. Bethesda (MD): Office of Dietary Supplements, National Institutes of Health. 2011. Available from: http://ods.od.nih.gov/factsheets/vitaminD.
   Google Scholar
• Hollis BW, Kamerud JW, Selvaag SR, Lorenz JD, Napoli JL. Determination of vitamin D status by radioimmunoassay using I[125]-labelled tracer. Clin Chem 1993;39:529–33.
   PubMed Web of Science ®Google Scholar
• Skinner HG, Michaud DS, Giovannucci E, Willett WC, Colditz GA, Fuchs CS. Vitamin D intake and the risk for pancreatic cancer in two cohort studies. Cancer Epidemiol Biomarkers Prev 2006;15:1688–95.
   PubMed Web of Science ®Google Scholar
• Stolzenberg-Solomon RZ, Hayes RB, Horst RL, Anderson KE, Hollis BW, Silverman DT. Serum vitamin D and risk of pancreatic cancer in the prostate, lung, colorectal, and ovarian screening trial. Cancer Res 2009;69:1439–47.
   PubMed Web of Science ®Google Scholar
• Stolzenberg-Solomon RZ, Vieth R, Azad A, Pietinen P, Taylor PR, Virtamo J, et al.. A prospective nested case-control study of vitamin D status and pacreatic cancer risk in male smokers. Cancer Res 2006;66:10213–9.
   PubMed Web of Science ®Google Scholar
• Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, et al.. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982;5:649–55.
   PubMed Web of Science ®Google Scholar
• Peterlik M, Cross HS. Dysfunction of the vitamin D endocrine system as common causes for multiple malignant and other chronic diseases. Anticancer Res 2006;26:2581–8.
   PubMed Web of Science ®Google Scholar
• Lappe JM, Travers-Gustafson D, Davies KM, Recker RR, Heaney RP. Vitamin D and calcium supplementation reduces cancer risk: results of a randomized trial. Am J Clin Nutr 2007;85:1586–91.
   PubMed Web of Science ®Google Scholar
• Tangpricha V, Colon NA, Kaul H, Wang SL, Decastro S, McFadden ET, et al.. Prevalence of vitamin D deficiency in patients attending an outpatient cancer care clinic in Boston. Endocr Pract 2004;10:292–3.
   PubMedGoogle Scholar
• Holick MF. Vitamin D; its role in cancer prevention and treatment. Prog Biophys Mol Biol 2006;92:549–59.
   Web of Science ®Google Scholar
• Abe E, Miyaura C, Sakagami H, Takeda M, Konno K, Yamazaki T, et al.. Differentiation of mouse myeloid leukemia cells induced by 1[alpha],25-dihydroxyvitamin D3. Proc Natl Acad Sci USA 1981;78:4990–4.
   PubMed Web of Science ®Google Scholar
• Honma Y, Hozumi M, Abe E, Konno K, Fukushima M, Hata S, et al.. 1[alpha],25-dihydroxyvitamin D3 and 1[alpha]-hydroxyvitamin D3 prolong survival time of mice inoculated with myeloid leukemia cells. Proc Natl Acad Sci USA 1983;80:201–4.
   PubMed Web of Science ®Google Scholar
• Ahn J, Peters U, Albanes D, Purdue HP, Abnet CC, Chatterjee N, et al.. Serum vitamin D concentration and prostate cancer risk: a nested case-control study. J Natl Cancer Inst 2008;100:796–804.
   PubMed Web of Science ®Google Scholar
• Porojnicu AC, Robsahm TE, Ree AH, Moan J. Season of prognosis is a prognostic factor in Hodgkin’s lymphoma: a possible role of sun-induced vitamin D. Br J Cancer 2005;93:571–4.
   PubMed Web of Science ®Google Scholar
• Porojnicu AC, Robsahm TE, Dahlback A, Berg JP, Christiani D, Bruland OS, et al.. Seasonal and geographical variations in lung cancer prognosis in Norway. Does vitamin D from the sun play any role? Lung Cancer 2007;55:263–70.
   PubMed Web of Science ®Google Scholar
• Lim HS, Roychoudhuri R, Peto J, Schwartz G, Baade P, Møller H. Cancer survival is dependent on season of diagnosis and sunlight exposure. Int J Cancer 2006;119:1530–6.
   PubMed Web of Science ®Google Scholar
• Wortsman J, Matsuoka LY, Chen TC, Lu Z, Holick MF. Decreased bioavailability of vitamin D in obesity. Am J Clin Nutr 2000;72:690–3.
   PubMed Web of Science ®Google Scholar
• Holick MF. The use and interpretation of assays for vitamin D and its metabolites. J Nutr 1990;120(Suppl. 11):1464–9.
   PubMed Web of Science ®Google Scholar
• Wu K, Feskanich D, Fuchs CS, Willett WC, Willett WC, Hollis BW, Giovannucci EL. A nested case control study of plasma 25-hydroxyvitamin D concentrations and risk of colorectal cancer. J Natl Cancer Inst 2007;99:1120–29.
   PubMed Web of Science ®Google Scholar
• Dunlap N, Schwartz GG, Eads D, Cramer SD, Sherk AB, John V, et al.. 1α,25-Dihydroxyvitamin D3 (calcitriol) and its analogue, 19-nor-1α,25(OH)2D2 potentiate the effect of ionising radiation on human prostate cancer cells. Br J Cancer 2003;89:746–53.
   PubMed Web of Science ®Google Scholar
• Deeb KK, Trump DL, Johnson CS. Vitamin D: signalling pathways in cancer: potential for anticancer therapeutics. Nat Rev Cancer 2007;7:684–700.
   PubMed Web of Science ®Google Scholar
• Politzer WM. Long-term clinical remission of chronic lymphocytic leukaemia by dietary means. South African Med J 2005;95:321–2.
   PubMed Web of Science ®Google Scholar
• Berman E, Nicolaides M, Maki RG, Fleisher M, Chanel S, Scheu K, et al.. Altered bone and mineral metabolism in patients receiving imatinib mesylate. N Engl J Med 2006;354:2006–13.
   PubMed Web of Science ®Google Scholar
• Grey A, O’Sullivan S, Reid IR, Browett P. Imatinib mesylate increased bone formation, and secondary hyperparathyroidism. N Engl J Med 2006;355:2494–5.
   PubMed Web of Science ®Google Scholar
• Fitter S, Dewar AL, Kostakis P, To LB, Hughes TP, Roberts MM, et al.. Long-term imatinib therapy promotes bone formation in CML patients. Blood 2008;111:2538–47.
   PubMed Web of Science ®Google Scholar
• Osorio S, Noblejas AG, Duran A, Steegmann JL. Imatinib mesylate induces hypophosphatemia in patients with chronic myeloid leukemia in late chronic phase, and this effect is associated with response. Am J Hematol 2007;82:394–5.
   PubMed Web of Science ®Google Scholar
• Vandyke K, Fitter S, Dewar AL, Hughes TP, Zannettino ACW. Dysregulation of bone remodeling by imatinib mesylate. Blood 2010;115:766–74.
   PubMed Web of Science ®Google Scholar
• Ng K, Meyerhardt JA, Wu K, Feskanich D, Hollis BW, Giovannucci EL, et al.. Circulating 25-hydroxyvitamin D levels and survival in patients with colorectal cancer. J Clin Oncol 2008;36:2984–91.
   Google Scholar